Trifluridine/tipiracil hydrochloride mixture

TargetMol
Product Code: TAR-T3658
Supplier: TargetMol
CodeSizePrice
TAR-T3658-2mg2mg£97.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3658-5mg5mg£112.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3658-1mL1 mL * 10 mM (in DMSO)£128.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3658-10mg10mg£142.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3658-25mg25mg£198.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3658-50mg50mg£282.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3658-100mg100mg£389.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3658-200mg200mg£551.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T3658-500mg500mg£822.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
TAS-102 is a novel oral combination drug containing trifluridine (TFT) and Tipiracil hydrochloride (TTP) in a molar ratio of 2:1.
CAS:
733030-01-8
Formula:
C29H34Cl2F6N8O12
Molecular Weight:
871.53
Pathway:
DNA Damage/DNA Repair; Cell Cycle/Checkpoint
Purity:
0.9982
SMILES:
Cl.Clc1c(CN2CCCC2=N)[nH]c(=O)[nH]c1=O.OC[C@@H]1O[C@H](C[C@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F.OC[C@@H]1O[C@H](C[C@H]1O)n1cc(c(=O)[nH]c1=O)C(F)(F)F
Target:
Nucleoside Antimetabolite/Analog; DNA/RNA Synthesis

References

Luo P Q, Zhang L X, Chen Z M, et al.Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer.Cell Cycle.2023: 1-15. Nukatsuka M, et al. Anticancer Res. 2015, 35(9):4605-15. Lenz HJ, et al. Cancer Treat Rev. 2015, 41(9):777-83.